BACKGROUND: Globally, herpes simplex virus type 2 (HSV-2) infection is the most common cause of genital ulcer disease. Effective prevention strategies for HSV-2 infection are needed to achieve the goals of the World Health Organization global strategy for the prevention and control of sexually transmitted infections. METHODS: We assessed the effectiveness of pericoital tenofovir gel, an antiviral microbicide, in preventing HSV-2 acquisition in a subgroup of 422 HSV-2-negative women enrolled in the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 study, a double-blind, randomized, placebo-controlled trial. Incident HSV-2 cases were identified by evidence of seroconversion on an HSV-2 IgG enzyme-linked immunosorbent assay between study enrollment and exit. A confirmatory analysis was performed by Western blot testing. RESULTS: The HSV-2 incidence rate was 10.2 cases per 100 person-years (95% confidence interval [CI], 6.8 to 14.7) among 202 women assigned to tenofovir gel, as compared with 21.0 cases per 100 person-years (95% CI, 16.0 to 27.2) among 222 women assigned to placebo gel (incidence rate ratio, 0.49; 95% CI, 0.30 to 0.77; P=0.003). The HSV-2 incidence rate among the 25 women with vaginal tenofovir concentrations of 10,000 ng per milliliter or more was 5.7 cases per 100 person-years, as compared with 15.5 cases per 100 person-years among the 103 women with no detectable vaginal tenofovir (incidence rate ratio, 0.37; 95% CI, 0.04 to 1.51; P=0.14). As confirmed by Western blot testing, there were 16 HSV-2 seroconversions among women assigned to tenofovir gel as compared with 36 among those assigned to the placebo gel (incidence rate ratio, 0.45; 95% CI, 0.23 to 0.82; P=0.005). CONCLUSIONS: In this study in South Africa, pericoital application of tenofovir gel reduced HSV-2 acquisition in women. (Funded by the U.S. Agency for International Development and others; ClinicalTrials.gov number, NCT00441298.).
RCT Entities:
BACKGROUND: Globally, herpes simplex virus type 2 (HSV-2) infection is the most common cause of genital ulcer disease. Effective prevention strategies for HSV-2 infection are needed to achieve the goals of the World Health Organization global strategy for the prevention and control of sexually transmitted infections. METHODS: We assessed the effectiveness of pericoital tenofovir gel, an antiviral microbicide, in preventing HSV-2 acquisition in a subgroup of 422 HSV-2-negative women enrolled in the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 study, a double-blind, randomized, placebo-controlled trial. Incident HSV-2 cases were identified by evidence of seroconversion on an HSV-2 IgG enzyme-linked immunosorbent assay between study enrollment and exit. A confirmatory analysis was performed by Western blot testing. RESULTS: The HSV-2 incidence rate was 10.2 cases per 100 person-years (95% confidence interval [CI], 6.8 to 14.7) among 202 women assigned to tenofovir gel, as compared with 21.0 cases per 100 person-years (95% CI, 16.0 to 27.2) among 222 women assigned to placebo gel (incidence rate ratio, 0.49; 95% CI, 0.30 to 0.77; P=0.003). The HSV-2 incidence rate among the 25 women with vaginal tenofovir concentrations of 10,000 ng per milliliter or more was 5.7 cases per 100 person-years, as compared with 15.5 cases per 100 person-years among the 103 women with no detectable vaginal tenofovir (incidence rate ratio, 0.37; 95% CI, 0.04 to 1.51; P=0.14). As confirmed by Western blot testing, there were 16 HSV-2 seroconversions among women assigned to tenofovir gel as compared with 36 among those assigned to the placebo gel (incidence rate ratio, 0.45; 95% CI, 0.23 to 0.82; P=0.005). CONCLUSIONS: In this study in South Africa, pericoital application of tenofovir gel reduced HSV-2 acquisition in women. (Funded by the U.S. Agency for International Development and others; ClinicalTrials.gov number, NCT00441298.).
Authors: Deborah Tien; Roger L Schnaare; Feirong Kang; Gina Cohl; Timothy J McCormick; Thomas R Moench; Gustavo Doncel; Karen Watson; Robert W Buckheit; Mark G Lewis; Jill Schwartz; Karen Douville; Joseph W Romano Journal: AIDS Res Hum Retroviruses Date: 2005-10 Impact factor: 2.205
Authors: Julie B Dumond; Rosa F Yeh; Kristine B Patterson; Amanda H Corbett; Byung Hwa Jung; Naser L Rezk; Arlene S Bridges; Paul W Stewart; Myron S Cohen; Angela D M Kashuba Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: Philippe Van de Perre; Michel Segondy; Vincent Foulongne; Abdoulaye Ouedraogo; Issouf Konate; Jean-Marie Huraux; Philippe Mayaud; Nicolas Nagot Journal: Lancet Infect Dis Date: 2008-08 Impact factor: 25.071
Authors: Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Emily T Martin; Elizabeth Krantz; Sami L Gottlieb; Amalia S Magaret; Andria Langenberg; Lawrence Stanberry; Mary Kamb; Anna Wald Journal: Arch Intern Med Date: 2009-07-13
Authors: Aaron A R Tobian; David Serwadda; Thomas C Quinn; Godfrey Kigozi; Patti E Gravitt; Oliver Laeyendecker; Blake Charvat; Victor Ssempijja; Melissa Riedesel; Amy E Oliver; Rebecca G Nowak; Lawrence H Moulton; Michael Z Chen; Steven J Reynolds; Maria J Wawer; Ronald H Gray Journal: N Engl J Med Date: 2009-03-26 Impact factor: 91.245
Authors: Lisa M Noguchi; Elizabeth T Montgomery; Joseph R Biggio; Craig W Hendrix; Debra L Bogen; Sharon L Hillier; James Y Dai; Jeanna M Piper; Mark A Marzinke; Charlene S Dezzutti; S Karen Isaacs; Jill L Schwartz; D Heather Watts; Richard H Beigi Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191
Authors: Ekaterina Taneva; Kerry Crooker; Sung Hyun Park; Jonathan T Su; Adina Ott; Natalia Cheshenko; Igal Szleifer; Patrick F Kiser; Bruce Frank; Pedro M M Mesquita; Betsy C Herold Journal: Antimicrob Agents Chemother Date: 2015-12-28 Impact factor: 5.191
Authors: Nicolas Çuburu; Selina Khan; Cynthia D Thompson; Rina Kim; Jort Vellinga; Roland Zahn; Douglas R Lowy; Gert Scheper; John T Schiller Journal: Int J Cancer Date: 2017-12-01 Impact factor: 7.396
Authors: Ekaterina Taneva; Shada Sinclair; Pedro Mm Mesquita; Brian Weinrick; Scott A Cameron; Natalia Cheshenko; Kerry Reagle; Bruce Frank; Sujatha Srinivasan; David Fredricks; Marla J Keller; Betsy C Herold Journal: JCI Insight Date: 2018-07-12